Simple liquid biopsy enables targeted therapies in castration-resistant prostate cancer


Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs. In this video Dr. Howard Scher explains how the formulation of a unique assay, performed by a simple “liquid biopsy” or blood test, is enabling a clearer understanding of the mechanisms underlying resistance to these drugs and will facilitate selection of more targeted therapies in many patients.

Further Reading

Refer a Patient
Call our dedicated clinician access number at 646-677-7440 or click the link below, and one of our care advisors will assist you with your referral needs.